Showing 98,341 - 98,360 results of 101,671 for search '(( 12 men decrease ) OR ( 5 ((((step decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.44s Refine Results
  1. 98341
  2. 98342
  3. 98343
  4. 98344
  5. 98345
  6. 98346
  7. 98347
  8. 98348
  9. 98349

    Image_1_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  10. 98350

    Image_4_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  11. 98351

    Image_3_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  12. 98352

    Image_2_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  13. 98353

    Table_1_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.docx by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  14. 98354

    Genome-wide complementary agonist and antagonist screens of host-encoded miRNAs impacting henipavirus infection at BSL-4. by Chwan Hong Foo (2571913)

    Published 2016
    “…(B and C) Results from the miRNA agonist (B) and antagonist (C) screens, with miRNAs ranked using a robust Z-score approach, from lowest (decreased virus infection) to highest (increased virus infection). …”
  15. 98355
  16. 98356

    DataSheet_1_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.docx by Hongyan Cheng (445898)

    Published 2021
    “…We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1–2×10<sup>9</sup> cells and a dose-climbing strategy. …”
  17. 98357
  18. 98358

    Image_1_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1–2×10<sup>9</sup> cells and a dose-climbing strategy. …”
  19. 98359

    Image_3_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1–2×10<sup>9</sup> cells and a dose-climbing strategy. …”
  20. 98360